Related Experiment Video
Updated: Jul 10, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Genetic polymorphism of CYP2C19 in Maharashtrian population
Yogita Ghodke1, Kalpana Joshi, Yashendra Arya
1Bioprospecting Laboratory, Interdisciplinary School of Health Sciences, University of Pune, Pune, 411007, Maharashtra, India.
European Journal of Epidemiology
|November 6, 2007
Summary
Genetic variations in the CYP2C19 gene impact drug metabolism and response. This study reveals unique CYP2C19 allele and genotype frequencies in the Maharashtrian population, distinct from other Indian and global groups.
Area of Science:
- Pharmacogenomics
- Human Genetics
- Drug Metabolism
Background:
- Inter-individual variability in drug response is influenced by genetic polymorphisms in drug-metabolizing enzymes.
- Cytochrome P450 enzymes (CYP), particularly CYP2C19, are crucial for metabolizing numerous medications.
- Limited data exists on CYP2C19 gene polymorphism frequencies in diverse Indian ethnic groups, including the Maharashtrian population.
Purpose of the Study:
- To determine the allele and genotype frequencies of major CYP2C19 variants in the Maharashtrian population.
- To compare these frequencies with those reported in other Indian and global populations.
- To investigate potential ethnic-specific variations in CYP2C19 in Western India.
Main Methods:
- Genotyping of major allelic variants of the CYP2C19 gene.
- Analysis of 139 unrelated healthy Maharashtrian subjects.
- Comparative analysis and meta-analysis with existing population data.
Main Results:
- This study provides the first report on CYP2C19 allele and genotype frequencies in the Maharashtrian population.
- The Maharashtrian population exhibits distinct genetic profiles compared to Caucasians, Africans, and some Asian populations.
- Significant genetic heterogeneity was observed among different Indian subpopulations.
Conclusions:
- The Maharashtrian population's CYP2C19 genetic makeup is unique, highlighting the need for population-specific pharmacogenetic studies.
- Understanding these variations is essential for optimizing drug therapy and minimizing adverse drug reactions in this ethnic group.
- This research underscores the importance of considering sub-ethnic diversity within India for personalized medicine approaches.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...